Novo Nordisk praises on the stock exchange – this is because of this

Danish pharmaceutical Novo Nordisk On Friday, it reports positive results on the early study of its amycretin diet drug.

Novo’s share was about 14 % after half past three in the afternoon on the Copenhagen Stock Exchange.

According to Novo Nordisk, a once -a -week drug led to a 22 % weight loss in a 36 -week study, while the weight of patients eating placebo was on average 2 %.

Novo’s well-known diabetes and diet drugs Wegovy and Ozempic are both semaglutide preparations given in injections. Novo also aims to develop a new amycretin product in the tablet form.

Like Wegovy and Ozempic, amycretin mimics the intestinal hormone GLP-1, but also the effect of amyline hormone in the pancreas that curb the appetite. Thus, amycretin is a dual -acting drug.

Novo’s main competitors of a US drug manufacturer Ie lillyn The share was declining by a 0.5 per cent in the Wall Street pre -trading. The day before, Lilly had reached 1.7 %.

Novo’s share collapsed in mid -December more than 20 percent after the study of the cagriseman dilation drug under development did not produce the desired results and the pressure on developing a new drug medicine is high.

Over the past year, Novo’s course is about nine percent minus, and at the beginning of this year, 3.3 percent rises.